NCT00298675View on ClinicalTrials.gov

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

May 31, 2011

Conditions
Tumors
Interventions
DRUG

BSI-201 (iniparib)

BSI-201 administered intravenously (IV), 2x weekly

DRUG

irinotecan

Irinotecan administered weekly, IV.

Trial Locations (3)

Unknown

Research Site, New Haven

Research Site, Houston

Research Site, San Antonio

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00298675 - Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter